Table 1.

Patient demographics and baseline characteristics at enrollment

	Non-Hodgkin's lymphoma	Hodgkin's disease	Multiple myeloma
Age (yr)
Mean (SD)	57.8 (14.5)	38.1 (15.2)	65.7 (10.9)
Median (range)	60.0 (18–87)	35.0 (18–89)	67.0 (31–94)
Age groups, n (%)
<40 yr	141 (12.8)	304 (61.2)	10 (1.4)
40–59 yr	393 (35.7)	131 (26.4)	185 (26.3)
60–69 yr	314 (28.5)	42 (8.5)	224 (31.8)
≥70 yr	254 (23.0)	20 (4.0)	285 (40.5)
Gender, n (%)
Male	564 (55.9)	257 (53.3)	332 (51.6)
Female	445 (44.1)	225 (46.7)	312 (48.4)
WHO score, n (%)
Grade 0	309 (28.4)	209 (41.9)	129 (18.7)
Grades 1–2	685 (62.9)	276 (55.3)	469 (68.1)
Grades 3–4	95 (8.7)	14 (2.8)	91 (13.2)
Disease status, n (%)
New diagnosis, no treatment	245 (22.3)	143 (28.3)	93 (13.3)
New diagnosis, treatment	247 (22.5)	167 (33.0)	102 (14.6)
P/R	412 (37.5)	100 (19.8)	381 (54.7)
Remission	195 (17.7)	96 (19.0)	121 (17.4)
Treatment status, n (%)
None	474 (43.6)	229 (45.9)	318 (46.2)
Radiotherapy (RT)	15 (1.4)	18 (3.6)	14 (2.0)
Chemotherapy (CT)	595 (54.7)	250 (50.1)	341 (49.5)
Concomitant RT/CT	4 (0.4)	2 (0.4)	16 (2.3)
Hb level (g/dL)
Mean (SD)	12.0 (2.1)	12.6 (1.9)	11.0 (1.9)
Median (range)	12.0 (5.0–17.2)	12.6 (5.6–18.4)	11.0 (5.6–18.1)
Hb category, n (%)
<8.0 g/dL	30 (2.8)	6 (1.2)	31 (4.6)
8.0–9.9 g/dL	157 (14.6)	37 (7.4)	171 (25.1)
10.0–11.9 g/dL	342 (31.7)	144 (28.8)	269 (39.5)
≥12 g/dL	550 (51.0)	313 (62.6)	210 (30.8)
Weight (kg)
Mean (SD)	71.9 (14.3)	71.2 (16.3)	70.7 (15.0)
Median (range)	70.0 (39–150)	68.5 (39–162)	69.0 (35-250)
BMI
Mean (SD)	21.3 (3.7)	20.8 (4.1)	21.3 (4.1)
Median (range)	21.1 (12.7–42.2)	20.0 (12.0–40.0)	20.9 (12.1–78.1)

SD, standard deviation; BMI, body mass index.